The research, led by Vasiliki Galani and Matthaios Speletas of the University of Thessaly together with collaborators from Papageorgiou General Hospital in Thessaloniki, applied a targeted sequencing panel covering twelve genes implicated in hereditary hemochromatosis and in iron homeostasis more broadly. Rather than screening only the classic HFE gene, which accounts for the majority of cases in populations of Northern European descent, the panel interrogated the wider genetic landscape of iron metabolism, including genes such as HJV, HAMP, TFR2, SLC40A1, and ERFE. This broader approach reflects a growing recognition that non-HFE forms of the disease, though individually rare, collectively represent a meaningful share of patients, particularly in Mediterranean populations where variant distributions differ from the Northern European canon.

Technically, the workflow was deliberately conservative and rigorous. Sequencing results were interpreted according to the guidelines of the American College of Medical Genetics and Genomics, the standard framework that classifies variants into five tiers ranging from benign to pathogenic. Every finding was then confirmed by conventional PCR followed by Sanger sequencing, the older but highly accurate method that remains the gold standard for validating individual variants called by high-throughput platforms. This two-step strategy guards against false positives, an ever-present concern when sequencing pipelines involve enzymatic amplification, alignment algorithms, and variant-calling software that can each introduce artifacts.

The clinical payoff of this approach was illustrated by a case supporting a diagnosis of juvenile hemochromatosis, the aggressive early-onset form of the disease caused by mutations in genes such as HJV and HAMP. The team identified the established pathogenic HJV p.Gly320Val variant, a well-characterized substitution that swaps a glycine for a valine at position 320 of the hemojuvelin protein. Juvenile hemochromatosis typically manifests before the age of thirty, with severe iron loading, cardiomyopathy, hypogonadism, and endocrine damage, and it behaves very differently from the adult HFE-related form. Distinguishing it early is not an academic exercise: therapeutic intensity, family screening, and monitoring schedules all hinge on knowing which genetic subtype a patient carries.

Perhaps the most scientifically intriguing finding was an ultra-rare variant of uncertain significance in the ERFE gene, designated c.478G>A, or p.Ala160Thr. ERFE encodes erythroferrone, a hormone produced by developing red blood cells that suppresses hepcidin, the master hormonal regulator of iron absorption and release. The variant is so rare that existing databases and literature provide no evidence about its clinical consequences, which is precisely why it falls into the variant of uncertain significance category. Faced with such ambiguity, the researchers turned to structural biology, using AlphaFold3 to model the three-dimensional consequences of the amino acid substitution and visualizing the results in PyMOL.

The structural modeling suggested that the p.Ala160Thr substitution could potentially alter properties that affect protein function, though the investigators were careful to frame this as suggestive rather than conclusive. This is where the study touches on one of the liveliest debates in modern genomics: what to do with variants of uncertain significance. Returning an ambiguous result to a patient can create anxiety and, in the worst case, misdirect clinical decisions. But dismissing such variants outright risks missing genuine disease causes. The Greek team’s approach, pairing sequencing with protein structural prediction, offers a middle path, generating mechanistic hypotheses that can guide future functional studies without overclaiming pathogenicity in the present.

A third finding served as an internal quality control rather than a clinical discovery. The established pathogenic SLC40A1 p.Arg178Gln variant, affecting the ferroportin iron exporter, was detected in a control sample. Far from undermining the study, this observation validated the robustness of the methodology, demonstrating that the panel reliably detects known pathogenic variants even in individuals who were not the primary subjects of investigation. Quality assurance of this kind matters enormously in clinical genomics, where a missed variant can mean a missed diagnosis and a delayed intervention for a family member who has inherited the same mutation.

The broader context of the work is the steady migration of hemochromatosis diagnostics from single-gene testing toward comprehensive molecular panels. Historically, diagnosis relied on a combination of transferrin saturation, serum ferritin, and HFE genotyping, which works reasonably well for the common C282Y homozygous genotype but fails patients with rarer genetic architectures. Patients with unexplained hyperferritinemia, a common clinical referral trigger, frequently cycle through liver biopsies, imaging studies, and repeat blood tests without ever receiving a molecular answer. A twelve-gene panel collapses this diagnostic odyssey into a single assay, and the authors argue that this, in turn, enables more personalized management strategies tailored to the specific genetic defect underlying each patient’s iron overload.

There are limits worth acknowledging. AlphaFold3’s predictions describe protein structure, not function, and a plausible structural perturbation does not prove that a variant disrupts erythroferrone signaling in living cells. Functional assays, segregation studies in families, and accumulation of additional cases will be needed to reclassify variants like ERFE p.Ala160Thr. Nonetheless, the study offers a template for how clinical genetics laboratories can responsibly handle uncertainty: sequence broadly, interpret under established frameworks, confirm rigorously, and use structural modeling to add a layer of mechanistic plausibility without overstating the evidence. As sequencing costs continue to fall and structural prediction tools grow more accurate, that template may well become the standard against which iron disorder diagnostics are measured, converting a historically underdiagnosed condition into one where the genetic answer, more often than not, is within reach.

Subject of Research: Targeted next-generation sequencing for the molecular diagnosis of hereditary hemochromatosis

Article Title: Targeted next-generation sequencing in the molecular diagnosis of hereditary hemochromatosis

Article References: Galani, V., Apostolou, C., Kalala, F., Galanopoulos, A. P., Sarrou, S., Papchianou, E., Matziri, A., Gkousiaris, D. F., Zachou, K., Dalekos, G., Hadjichristodoulou, C., Kioumi, A., & Speletas, M. (2026). Targeted next-generation sequencing in the molecular diagnosis of hereditary hemochromatosis. Annals of Hematology. https://doi.org/10.1007/s00277-026-07269-6

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07269-6

Keywords: hereditary hemochromatosis, next-generation sequencing, juvenile hemochromatosis, HJV, ERFE, erythroferrone, SLC40A1, variants of uncertain significance, AlphaFold3, iron metabolism, genetic diagnostics, hyperferritinemia

The clinical problem the team set out to address is well known in genomic medicine. Molecular diagnosis of rare disease currently plateaus at roughly fifty percent of patients, even after whole exome or whole genome sequencing. A substantial share of those unresolved cases involves variants that alter splicing, the process by which RNA transcripts are cut and re-joined to produce mature messenger RNA. Predicting whether a DNA change actually disrupts splicing in a patient’s tissues remains notoriously difficult, and variants of uncertain significance accumulate in reports without a practical way to test their effects directly.

Short-read RNA sequencing, which fragments transcripts into small pieces before reading them, often cannot show how exons connect across a whole transcript. Long-read platforms from Oxford Nanopore Technologies solve this by reading RNA-derived molecules end to end, revealing full isoform structures. Until now, however, long-read RNA approaches have typically demanded large control cohorts, complex bioinformatics and tissue samples that are hard to obtain, keeping them confined to specialist research laboratories rather than routine diagnostics.

RAPID, short for RNA Analysis Pipeline for Integrated Diagnostics, was designed from the outset to be diagnostically deployable. It is fully modular, covering the entire sample-to-answer journey, from primer design targeting genes of interest through nanopore sequencing to reproducible single-sample interpretation. Cases entered the workflow after exome or genome sequencing and multidisciplinary team review had narrowed the search to five or fewer candidate genes, meaning the sequencing effort could be focused and fast. Crucially, the method relies on accessible tissues such as blood and does not require large control datasets for interpretation.

The study applied the workflow to six probands with suspected monogenic neurometabolic disease, and the outcomes illustrate three distinct diagnostic scenarios. In two cases, targeted long-read RNA sequencing confirmed pathogenic splice disruption at the transcript level, converting uncertainty into a resolved molecular diagnosis. In one case, the RNA evidence argued against a candidate gene, prompting its exclusion and redirecting the diagnostic search. In the remaining three cases, transcript-level findings prioritised further DNA investigation, refining how the variants of uncertain significance should be weighed.

Technically, the workflow captured amplicons spanning the relevant exons and splice junctions of each candidate gene, generating reads long enough to assemble near-full-length isoform structures. The team demonstrated reproducibility by showing consistent isoform composition for a control gene across commercial blood RNA samples and an independent public long-read dataset, and they characterised the minimum read depth needed to detect transcripts at low fractional abundance. Quality control metrics, including read length and depth, were achieved using standard long-read sequencing infrastructure within a clinically relevant timeframe.

The authors also mapped their RNA results onto the established variant interpretation framework used by clinical scientists, in which aberrant splicing leading to frameshifts or premature stop codons, particularly in transcripts subject to nonsense-mediated decay, can support pathogenic classifications. By providing direct, mechanism-level evidence rather than in silico predictions, the workflow strengthens this evidence hierarchy and gives diagnostic laboratories a practical route to resolving variants that would otherwise remain reportable only as uncertain.

The significance for patients and families is considerable. A definitive molecular diagnosis can end a diagnostic odyssey that sometimes lasts decades, inform prognosis, guide surveillance and treatment, enable accurate genetic counselling, and open doors to targeted therapies and clinical trials. For a field in which half of patients still leave the sequencing process without answers, a rapid, cost-effective test that interrogates RNA directly addresses one of the largest remaining diagnostic gaps.

The researchers argue that RAPID shows long-read RNA sequencing can be implemented within existing diagnostic infrastructure, offering a scalable path to routine transcript-level assessment in clinical genomics. As nanopore sequencing becomes more widespread in NHS and hospital laboratories, workflows of this kind could shift splicing variant interpretation from probabilistic prediction to direct functional measurement. Supported by funding from the charity Sparks and conducted with appropriate ethical approvals and participant consent, the study points toward a future in which reading the transcript itself becomes a standard step in solving rare disease.

The biological importance of splicing in human disease provides useful context for why this approach matters. Introns interrupt most human genes, and their precise removal depends on short sequence signals at exon boundaries that are frequently disrupted by single-nucleotide changes lying well outside protein-coding regions. Because such variants often sit in positions that protein-prediction tools ignore, they can be classified as benign or left as uncertain even when they silently abolish a transcript. Deep intronic changes can also activate cryptic exon inclusion, an effect essentially invisible to standard exome analysis, which is one reason splice-altering variation has been described as a substantial hidden burden within the undiagnosed fraction of rare disease cohorts.

The interpretation framework applied in the study reflects a broader international movement toward using RNA evidence in clinical classification. Guidelines from professional bodies now allow aberrant splicing demonstrated at the transcript level to contribute to pathogenic classifications, provided the altered transcript is shown to escape nonsense-mediated decay or to produce a clearly deleterious product. This matters because a large proportion of loss-of-function variants predicted to trigger nonsense-mediated decay are already treated as pathogenic by default; demonstrating experimentally that a variant of uncertain significance produces the same consequence effectively moves it into that well-established category. Conversely, showing that a candidate variant leaves splicing intact can be equally decisive, as the gene-exclusion case in this cohort illustrates.

Tissue choice is a central consideration for any transcript-based diagnostic test. Genes are not expressed uniformly across the body, and the reference resources that underpin transcript interpretation, such as population-scale tissue atlases, show that many disease-relevant genes have their highest expression in tissues that cannot ethically or practically be sampled. Blood, however, is accessible, and the workflow’s reliance on peripheral blood RNA, collected in standard preservation tubes and stored frozen, means the logistics resemble those of routine clinical phlebotomy rather than specialist tissue procurement. The supplementary analyses showing that isoform composition of a control gene is consistent across commercial RNA references and public datasets speak to the reproducibility that regulators and accreditation bodies would expect of a deployable assay.

The depth requirements characterised by the team address a practical question that any diagnostic laboratory must answer before adopting such a test: how much sequencing is enough. Because a deleterious transcript may represent only a small fraction of all transcripts from a given gene, particularly when nonsense-mediated decay degrades the abnormal product rapidly, sensitivity at low fractional abundance is essential. Mapping the relationship between transcript rarity and required read depth gives laboratories a principled basis for setting sequencing targets and quality thresholds rather than relying on ad hoc criteria.

The study also sits within a distinctive UK genomic infrastructure. Several participating families had previously been sequenced through national genome programmes, and the ethical frameworks governing those programmes permit recontact of participants for follow-up sampling, a mechanism that allowed the researchers to obtain fresh RNA from already-investigated patients. This recontact pathway, coordinated through clinical interpretation partnerships, represents a model for how long-read RNA follow-up could be layered onto existing genomic medicine services without requiring patients to restart the consent and recruitment process from scratch.

From a health-systems perspective, the economics of the approach deserve emphasis. Whole genome sequencing has become affordable at scale, but the interpretation bottleneck, not the sequencing itself, now limits diagnosis. A targeted assay that sequences only a handful of genes consumes modest sequencing capacity on instruments that many hospital laboratories already operate or can readily access, and the modular design means primer sets can be redesigned quickly for each new case. The near-full-length isoform output also reduces interpretive ambiguity, because the analyst sees the complete exon connectivity of each transcript rather than inferring it from fragmented short reads.

The neurometabolic focus of the cohort is itself informative. Leukodystrophies and related neurodegenerative conditions of childhood often present with nonspecific imaging findings and progressive symptoms, and several of the genes implicated in these disorders are known to harbour splice-disrupting variants that confound standard pipelines. For families facing such progressive conditions, the speed of the workflow is not merely convenient; an earlier molecular answer can determine eligibility for emerging therapies, some of which are most effective when started before irreversible neurological damage accumulates.

Looking forward, the study suggests a tiered model of genomic diagnosis in which short-read sequencing remains the first-line discovery tool, while targeted long-read RNA analysis serves as a rapid functional triage step for the subset of cases with splice-relevant candidates. The authors’ demonstration that results can be obtained within a clinically relevant timeframe, using standard infrastructure and single-sample interpretation without large control cohorts, positions transcript-level evidence to become a routine component of multidisciplinary review rather than a research exception reserved for specially funded projects.

Subject of Research: A targeted long-read RNA sequencing workflow for functionally resolving splicing variants in rare disease diagnosis

Article Title: RAPID: a targeted long-read RNA workflow for functional resolution of splicing variants in rare disease

Article References: Montgomery, K.-A., Macpherson, H., Anderson, C., Wade, C., Gustavsson, E. K., Lynch, D. S., Wilson, L. C., Davison, J., Wakeling, E., Tuschl, K., Houlden, H., Clement, E., Mills, P. B., & Ryten, M. (2026). RAPID: a targeted long-read RNA workflow for functional resolution of splicing variants in rare disease. Genome Medicine. https://doi.org/10.1186/s13073-026-01754-3

Image Credits: AI Generated

DOI: 10.1186/s13073-026-01754-3

Keywords: long-read RNA sequencing, Oxford Nanopore Technologies, splicing variants, rare disease diagnostics, variants of uncertain significance, neurometabolic disease, transcriptomics, molecular diagnosis, clinical genomics, whole exome sequencing, RNA splicing, diagnostic workflow

Researchers at The Hospital for Sick Children (SickKids) in Toronto have developed a machine-learning approach that could help resolve some of that uncertainty. The method converts blood-based epigenetic patterns into “tissue-agnostic” episignatures—molecular signals that can identify a genetic condition regardless of whether the DNA came from blood, amniotic fluid, placental tissue or another biological source. The advance could eventually make epigenetic testing more useful in prenatal medicine, where access to fetal tissues is limited and clinical decisions often must be made before birth.

The work focuses on epigenetics, the system of chemical modifications that regulates how genes operate without changing the underlying DNA sequence. One of the most important epigenetic mechanisms is DNA methylation, in which chemical groups attach to specific DNA bases and influence whether nearby genes are active or silent. Certain genetic disorders produce distinctive, disease-associated methylation patterns across the genome. These patterns, called episignatures, can act like molecular fingerprints, helping clinicians determine whether a genetic variant is likely to disrupt normal development.

The SickKids team, led by Clinical Geneticist and Senior Associate Scientist Rosanna Weksberg and Senior Research Associate Sanaa Choufani, has helped establish more than 60 episignatures. Many have already been clinically validated for diagnostic use. Traditionally, however, these signatures have been considered tissue-specific. A methylation pattern identified in blood might not be directly applicable to DNA extracted from prenatal samples, because different tissues undergo distinct developmental and regulatory processes. That limitation has prevented many families undergoing prenatal testing from benefiting from episignature-based analysis.

To test whether this barrier could be overcome, the researchers first generated a blood-derived episignature for Down syndrome, a condition caused in most cases by an extra copy of chromosome 21. The signature was built using samples from 266 people with Down syndrome. The team then used publicly available DNA methylation data from 850 individuals with and without the condition to train a machine-learning model. The dataset included six prenatal and postnatal tissue types, allowing the researchers to compare disease-associated methylation patterns across tissues with very different biological functions.

Rather than searching for a single methylation site, the model analyzed coordinated changes across numerous regions of the genome. Machine-learning algorithms can identify combinations of features that are difficult to recognize through manual inspection, including patterns that remain biologically meaningful even when their strength varies between tissues. In this case, the model was designed to preserve the core information of the blood-derived Down syndrome signature while adapting it to the molecular characteristics of other tissues.

The results demonstrated that the transformed signature accurately recognized the Down syndrome pattern in every tissue type tested. This finding suggests that a blood-derived episignature can be computationally converted into a broader diagnostic signal without losing its ability to distinguish affected and unaffected samples. The result does not mean that every genetic condition will produce a universal signature, but it provides proof that tissue-specificity—one of the major challenges in epigenetic diagnostics—may be reduced with carefully trained models and sufficiently diverse reference data.

The potential clinical impact is particularly important for prenatal diagnosis. Amniotic fluid and placental tissue may be available during pregnancy, but they are not equivalent to blood and can contain limited amounts of DNA. A tissue-agnostic episignature could allow clinicians to compare prenatal methylation data with established diagnostic patterns even when the original signature was discovered in postnatal blood. In practical terms, the approach could help interpret uncertain variants and provide families with more precise information at a time when uncertainty can have profound emotional and medical consequences.

The researchers also believe the strategy could eventually expand testing beyond conventional blood samples. Saliva and oral swabs, which are easier and less invasive to collect, may become useful sources of DNA if their molecular signals can be reliably connected to disease-associated episignatures. Such applications would require extensive validation across larger and more diverse populations, as well as careful assessment of false-positive and false-negative results. Machine-learning systems must also be tested in real clinical settings to ensure that their predictions remain reliable when samples vary in quality, ancestry, developmental stage and medical history.

The study, published in The American Journal of Human Genetics, represents an early but significant step toward more flexible epigenetic diagnostics. By combining genome-scale methylation analysis with machine learning, the SickKids team has shown that information discovered in one tissue can potentially be translated to others. The researchers say the long-term goal is to shorten the diagnostic odyssey experienced by many children and families affected by rare genetic disorders, while giving clinicians clearer evidence for interpreting uncertain variants. Supported by the Canadian Institutes of Health Research, the work could help advance a more individualized approach to prenatal and pediatric care, in which molecular data are used not only to diagnose disease but also to guide families through some of medicine’s most difficult decisions.

Subject of Research: Tissue-agnostic epigenetic signatures and machine-learning-assisted interpretation of genetic variants for prenatal diagnosis.

Web References: The American Journal of Human Genetics study; EpigenCentral; Rosanna Weksberg; SickKids Genetics & Genome Biology.

References: American Journal of Human Genetics; The Hospital for Sick Children; Canadian Institutes of Health Research.

Image Credits: The Hospital for Sick Children.

Keywords

Prenatal genetic testing, variants of uncertain significance, episignatures, DNA methylation, epigenetics, tissue-agnostic diagnostics, machine learning, Down syndrome, prenatal medicine, genetic disorders, medical genetics, SickKids

A pioneering study emerging from the laboratory of Dr. Jacob Kitzman at the University of Michigan Medical School sheds new light on this challenging landscape by focusing on the gene MUTYH—a crucial player in the maintenance of DNA integrity. MUTYH’s normal role involves the repair of oxidative DNA damage, a continuous threat to cellular genomes. Mutations in this gene compromise its repair ability and are implicated in the development of abnormal cellular growths, particularly polyps within the colon, which can progress to lethal colorectal cancer. Notably, risk variants in MUTYH are relatively common, with approximately 2% of the U.S. population carrying mutations that may elevate cancer susceptibility.

The study’s core innovation lies in its comprehensive functional interrogation of nearly every conceivable mutation in MUTYH. Traditional approaches to characterizing gene variants often involve painstakingly constructing individual cellular or animal models, each harboring a single mutation. This method, while informative, is labor-intensive and limits throughput. Instead, Kitzman and colleagues constructed a vast mutational library encompassing over 10,900 distinct MUTYH variants, representing an unprecedented saturation assessment of genetic changes within the gene.

To determine the functional consequences of these numerous mutations, the research team developed a sophisticated DNA-repair reporter system. This cellular assay acts as a molecular sensor: cells harboring functional MUTYH produce a fluorescent signal upon repairing oxidative DNA damage, illuminating in green. Conversely, dysfunctional mutations abrogate the repair process, leading to an absence of fluorescence. This binary readout enabled the high-throughput sorting of millions of cells into categories of fully functional, non-functional, and intermediate MUTYH activity.

The experimental data reveal compelling insights. Nonsense mutations—those introducing premature stop codons—predictably disrupted MUTYH function entirely. Synonymous variants, often called “silent” mutations because they do not alter protein sequence, displayed benign behavior. However, missense variants, which result in amino acid substitutions, painted a more nuanced picture. Many missense mutations induced graded functional impairments, forming a continuum from near-normal activity to severe loss of function. This spectrum suggests that the pathogenic potential of missense variants cannot be generalized and must be individually assessed.

Such detailed functional annotation of MUTYH variants bridges a critical gap between genetic testing and clinical interpretation. By comparing their results with the ClinVar repository—a curated database where clinicians classify the clinical significance of genetic variants—the researchers validated their assay’s accuracy. Strikingly, mutations previously identified in patients corresponded precisely with the functional categories delineated in the laboratory, including variants associated with milder disease phenotypes marked by late-onset polyp formation. This concordance bolsters confidence that the assay could refine clinical decision-making, potentially guiding prophylactic interventions.

The implications of this work extend beyond MUTYH. As genetic screening becomes increasingly routine, the field grapples with a surfeit of VUS across numerous disease-linked genes. Functional assays that systematically map the landscape of variant effects are essential to transform raw genetic data into actionable insights. Dr. Kitzman emphasizes this transition: “We can sequence genomes extensively, but interpreting how these sequences translate into disease risk remains a bottleneck. Tools like ours illuminate the meaning behind genetic letters, empowering prevention and personalized medicine.”

This breakthrough comes at a time when colon cancer remains a leading cause of cancer-related mortality worldwide. While inherited mutations in MUTYH account for only a fraction of cases, identifying carriers of high-risk variants affords the possibility of surveillance, early detection, and preventive measures that could be life-saving. The ability to stratify patients based on the functional impact of their specific mutations may revolutionize genetic counseling and targeted screening programs.

Yet, the journey from bench to bedside necessitates sustained investment in basic research. As Kitzman remarks, real-world benefits depend upon continued funding to unravel the detailed molecular underpinnings of cancer risk. This research exemplifies how marrying cutting-edge genomics with innovative functional assays can provide clarity where uncertainty has prevailed for decades.

In conclusion, the functional saturation mapping of MUTYH mutations sets a new paradigm for genetic variant interpretation in oncology. By illuminating the diverse functional consequences of mutations in a gene critical for DNA repair, Kitzman’s team offers a roadmap for harnessing the vast data generated by modern genomic technologies. Moving forward, the integration of such functional information with patient genetic screening will be instrumental in shifting cancer prevention from hopeful aspiration to precise reality.

Subject of Research: Functional characterization of MUTYH gene variants and their impact on colon cancer risk

Article Title: Saturation mapping of MUTYH variant effects using DNA repair reporters

Web References:
https://doi.org/10.1016/j.ajhg.2025.07.005

References:
Kitzman JO et al. “Saturation mapping of MUTYH variant effects using DNA repair reporters.” The American Journal of Human Genetics, 2025.

Keywords: Human genetics, colon cancer, MUTYH, DNA repair, genetic variants, missense mutations, functional genomics, hereditary cancer risk, cancer prevention, genomic screening